Sonen Capital’s 10x Genomics TXG Stock Holding History

Sonen Capital’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-4,866	Closed	-$220K	–	108
2022 Q2	$220K	Buy	+4,866	New	+$252K	0.31%	98

Other funds holding TXG

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

SIM

SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return

GIM

Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Sonen Capital's TXG Position: Q3 2022 in Review

Sonen Capital sold out of 10x Genomics (TXG) in Q3 2022, closing a stake of 4,866 shares — an estimated $220K sold.

Sonen Capital first reported a position in TXG in Q2 2022 and held it in 1 quarter. The position peaked at $220K in Q2 2022. 233 funds tracked by Wall St. Rank hold TXG as of Q3 2022.

Sonen Capital reported no remaining 10x Genomics position as of Q3 2022 after selling out during the quarter.
Sonen Capital sold 4,866 10x Genomics shares in Q3 2022, an estimated $220K.
Sonen Capital first reported a position in 10x Genomics in Q2 2022 and held it in 1 quarter.
Sonen Capital's 10x Genomics position peaked at $220K in Q2 2022.
233 funds tracked by Wall St. Rank held 10x Genomics as of Q3 2022.

Based on Sonen Capital's 13F filing for Q3 2022, filed 10 Nov 2022.